Progress and prospects in pharmacogenetics of antidepressant drugs

References

• Demyttenaere K, Bruffaerts R, Posada-Villa J, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the world health organization world mental health surveys. JAMA. 2004;291:2581–2590.
   PubMed Web of Science ®Google Scholar
• Global Burden of Disease Study Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;386:743–800.
   PubMed Web of Science ®Google Scholar
• Leucht S, Hierl S, Kissling W, et al. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry. 2012;200:97–106.
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28–40.
   PubMed Web of Science ®Google Scholar
• Souery D, Serretti A, Calati R, et al. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol. 2011;31:512–516.
   PubMed Web of Science ®Google Scholar
• O’Reilly RL, Bogue L, Singh SM. Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biol Psychiatry. 1994;36:467–471.
   PubMed Web of Science ®Google Scholar
• Pare CM, Rees L, Sainsbury MJ. Differentiation of two genetically specific types of depression by the response to anti-depressants. Lancet. 1962;2:1340–1343.
   PubMed Web of Science ®Google Scholar
• Franchini L, Serretti A, Gasperini M, et al. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res. 1998;32:255–259.
   PubMed Web of Science ®Google Scholar
• Fabbri C, Di Girolamo G, Serretti A. Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. Am J Med Genet B Neuropsychiatr Genet. 2013;162B:487–520.
   PubMed Web of Science ®Google Scholar
• Homberg JR, Lesch K-P. Looking on the bright side of serotonin transporter gene variation. Biol Psychiatry. 2011;69:513–519.
   PubMed Web of Science ®Google Scholar
• Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol. 2012;22:239–258.
   PubMed Web of Science ®Google Scholar
• Ma Y, Li B, Wang C, et al. Allelic variation in 5-HTTLPR and the effects of citalopram on the emotional neural network. Br J Psychiatry. 2015;206:385–392.
   PubMed Web of Science ®Google Scholar
• Shiroma PR, Drews MS, Geske JR, et al. SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a sequenced treatment alternatives to relieve depression (STAR*D) report. Am J Geriatr Psychiatry. 2014;22:1140–1148.
   PubMed Web of Science ®Google Scholar
• Pacheco J, Beevers CG, Benavides C, et al. Frontal-limbic white matter pathway associations with the serotonin transporter gene promoter region (5-HTTLPR) polymorphism. J Neurosci. 2009;29:6229–6233.
   PubMed Web of Science ®Google Scholar
• Vai B, Poletti S, Radaelli D, et al. Successful antidepressant chronotherapeutics enhance fronto-limbic neural responses and connectivity in bipolar depression. Psychiatry Res. 2015;233:243–253.
   PubMed Web of Science ®Google Scholar
• Qesseveur G, Petit AC, Nguyen HT, et al. Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: a translational approach. Neuropharmacology. 2016;105:142–153.
   PubMed Web of Science ®Google Scholar
• Lin J-Y, Jiang M-Y, Kan Z-M, et al. Influence of 5-HTR2A genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder: a meta-analysis. J Affect Disord. 2014;168:430–438.
   PubMed Web of Science ®Google Scholar
• Fabbri C, Marsano A, Albani D, et al. PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway. Pharmacogenomics J. 2014;14:463–472.
   PubMed Web of Science ®Google Scholar
• Laje G, Cannon DM, Allen AS, et al. Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB. Int J Neuropsychopharmacol. 2010;13:715–724.
   PubMed Web of Science ®Google Scholar
• Vermeer H, Hendriks-Stegeman BI, van der Burg B, et al. Glucocorticoid-induced increase in lymphocytic FKBP51 messenger ribonucleic acid expression: a potential marker for glucocorticoid sensitivity, potency, and bioavailability. J Clin Endocrinol Metab. 2003;88:277–284.
   PubMed Web of Science ®Google Scholar
• Guidotti G, Calabrese F, Anacker C, et al. Glucocorticoid receptor and FKBP5 expression is altered following exposure to chronic stress: modulation by antidepressant treatment. Neuropsychopharmacology. 2013;38:616–627.
   PubMed Web of Science ®Google Scholar
• Cattaneo A, Gennarelli M, Uher R, et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline ‘predictors’ and longitudinal ‘targets’. Neuropsychopharmacology. 2013;38:377–385.
   PubMed Web of Science ®Google Scholar
• Binder EB, Salyakina D, Lichtner P, et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet. 2004;36:1319–1325.
   PubMed Web of Science ®Google Scholar
• Niitsu T, Fabbri C, Bentini F, et al. Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:183–194.
   PubMed Web of Science ®Google Scholar
• Ruiz-Velasco V, Ikeda SR. A splice variant of the G protein beta 3-subunit implicated in disease states does not modulate ion channels. Physiol Genom. 2003;13:85–95.
   PubMed Web of Science ®Google Scholar
• Hu Q, Zhang SY, Liu F, et al. Influence of GNB3 C825T polymorphism on the efficacy of antidepressants in the treatment of major depressive disorder: a meta-analysis. J Affect Disord. 2014;172C:103–109.
   Google Scholar
• Glatt CE, Lee FS. Common polymorphisms in the age of research domain criteria (RDoC): integration and translation. Biol Psychiatry. 2016;79:25–31.
   PubMed Web of Science ®Google Scholar
• Govindarajan A, Rao BS, Nair D, et al. Transgenic brain-derived neurotrophic factor expression causes both anxiogenic and antidepressant effects. Proc Natl Acad Sci U S A. 2006;103:13208–13213.
   PubMed Web of Science ®Google Scholar
• GENDEP Investigators, MARS Investigators, STAR*D Investigators. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry. 2013;170:207–217.
   PubMed Web of Science ®Google Scholar
• Ricopili, a tool for visualizing regions of interest in selected GWAS data sets. Institute B. 2011. Available from: http://www.broadinstitute.org/mpg/ricopili/.
   Google Scholar
• Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000;85:11–28.
   PubMed Web of Science ®Google Scholar
• Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab. 2002;3:13–37.
   PubMed Web of Science ®Google Scholar
• Spina E, Scordo MG, D’Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol. 2003;17:517–538.
   PubMed Web of Science ®Google Scholar
• Bhagwat SV, Bhamre S, Boyd MR, et al. Cerebral metabolism of imipramine and a purified flavin-containing monooxygenase from human brain. Neuropsychopharmacology. 1996;15:133–142.
   PubMed Web of Science ®Google Scholar
• Manolopoulos VG. Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice. Clin Chem Lab Med. 2007;45:801–814.
   PubMed Web of Science ®Google Scholar
• Spina E, de Leon J. Clinical applications of CYP genotyping in psychiatry. J Neural Transm (Vienna). 2015;122:5–28.
   PubMed Web of Science ®Google Scholar
• Porcelli S, Fabbri C, Spina E, et al. Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. Expert Opin Drug Metab Toxicol. 2011;7:1101–1115.
   PubMed Web of Science ®Google Scholar
• Nelson DR, Zeldin DC, Hoffman SM, et al. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics. 2004;14:1–18.
   PubMedGoogle Scholar
• Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet. 2000;356:1667–1671.
   PubMed Web of Science ®Google Scholar
• Swen JJ, Nijenhuis M, De Boer A, et al. Pharmacogenetics: from bench to byte – an update of guidelines. Clin Pharmacol Ther. 2011;89:662–673.
   PubMed Web of Science ®Google Scholar
• Tsai M-H, Lin K-M, Hsiao M-C, et al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics. 2010;11:537–546.
   PubMed Web of Science ®Google Scholar
• Peters EJ, Slager SL, Kraft JB, et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS One. 2008;3:e1872.
   PubMed Web of Science ®Google Scholar
• Kawanishi C, Lundgren S, Agren H, et al. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol. 2004;59:803–807.
   PubMed Web of Science ®Google Scholar
• Rau T, Wohlleben G, Wuttke H, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther. 2004;75:386–393.
   PubMed Web of Science ®Google Scholar
• Zackrisson AL, Lindblom B, Ahlner J. High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases. Clin Pharmacol Ther. 2010;88:354–359.
   PubMed Web of Science ®Google Scholar
• Müller DJ, Kekin I, Kao AC, et al. Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic. Int Rev Psychiatry. 2013;25:554–571.
   PubMed Web of Science ®Google Scholar
• Spina E, Pisani F, de Leon J. Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. Pharmacol Res. 2016;106:72–86.
   PubMed Web of Science ®Google Scholar
• Linnet K. Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Hum Psychopharmacol. 2002;17:233–238.
   PubMed Web of Science ®Google Scholar
• Breyer-Pfaff U, Mey U, Green MD, et al. Comparative N-glucuronidation kinetics of ketotifen and amitriptyline by expressed human UDP-glucuronosyltransferases and liver microsomes. Drug Metab Dispos. 2000;28:869–872.
   PubMed Web of Science ®Google Scholar
• Zhou D, Guo J, Linnenbach AJ, et al. Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine. Drug Metab Dispos. 2010;38:863–870.
   PubMed Web of Science ®Google Scholar
• Iwai M, Maruo Y, Ito M, et al. Six novel UDP-glucuronosyltransferase (UGT1A3) polymorphisms with varying activity. J Hum Genet. 2004;49:123–128.
   PubMed Web of Science ®Google Scholar
• Mori A, Maruo Y, Iwai M, et al. UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metab Dispos. 2005;33:672–675.
   PubMed Web of Science ®Google Scholar
• Fowler S, Kletzl H, Finel M, et al. A UGT2B10 splicing polymorphism common in african populations may greatly increase drug exposure. J Pharmacol Exp Ther. 2015;352:358–367.
   PubMed Web of Science ®Google Scholar
• Fabbri C, Serretti A. Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications. Curr Psychiatry Rep. 2015;17:50.
   PubMed Web of Science ®Google Scholar
• Kato M, Fukuda T, Serretti A, et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:398–404.
   PubMed Web of Science ®Google Scholar
• Nikisch G, Eap CB, Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacol Res. 2008;58:344–347.
   PubMed Web of Science ®Google Scholar
• Uhr M, Tontsch A, Namendorf C, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008;57:203–209.
   PubMed Web of Science ®Google Scholar
• Sarginson JE, Lazzeroni LC, Ryan HS, et al. ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenet Genom. 2010;20:467–475.
   PubMed Web of Science ®Google Scholar
• Breitenstein B, Brückl TM, Ising M, et al. ABCB1 gene variants and antidepressant treatment outcome: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2015;168B:274–283.
   PubMed Web of Science ®Google Scholar
• Schatzberg AF, DeBattista C, Lazzeroni LC, et al. ABCB1 genetic effects on antidepressant outcomes: a report from the iSPOT-D trial. Am J Psychiatry. 2015;172:751–759.
   PubMed Web of Science ®Google Scholar
• Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–427.
   PubMed Web of Science ®Google Scholar
• Uher R, Perroud N, Ng MY, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry. 2010;167:555–564.
   PubMed Web of Science ®Google Scholar
• Garriock HA, Kraft JB, Shyn SI, et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry. 2010;67:133–138.
   PubMed Web of Science ®Google Scholar
• Ising M, Lucae S, Binder EB, et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry. 2009;66:966–975.
   PubMed Web of Science ®Google Scholar
• Myung W, Kim J, Lim S-W, et al. A genome-wide association study of antidepressant response in Koreans. Transl Psychiatry. 2015;5:e633.
   PubMed Web of Science ®Google Scholar
• Biernacka JM, Sangkuhl K, Jenkins G, et al. The international SSRI pharmacogenomics consortium (ISPC): a genome-wide association study of antidepressant treatment response. Transl Psychiatry. 2015;5:e553.
   PubMed Web of Science ®Google Scholar
• Sasayama D, Hiraishi A, Tatsumi M, et al. Possible association of CUX1 gene polymorphisms with antidepressant response in major depressive disorder. Pharmacogenomics J. 2013;13:354–358.
   PubMed Web of Science ®Google Scholar
• Wong M-L, Dong C, Flores DL, et al. Clinical outcomes and genome-wide association for a brain methylation site in an antidepressant pharmacogenetics study in Mexican Americans. Am J Psychiatry. 2014;171:1297–1309.
   PubMed Web of Science ®Google Scholar
• Tammiste A, Jiang T, Fischer K, et al. Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression. J Psychopharmacol. 2013;27:915–920.
   PubMed Web of Science ®Google Scholar
• O’Dushlaine C, Ripke S, Ruderfer DM, et al. Rare copy number variation in treatment-resistant major depressive disorder. Biol Psychiatry. 2014;76:536–541.
   PubMed Web of Science ®Google Scholar
• Tansey KE, Rucker JJ, Kavanagh DH, et al. Copy number variants and therapeutic response to antidepressant medication in major depressive disorder. Pharmacogenomics J. 2014;14:395–399.
   PubMed Web of Science ®Google Scholar
• Oksenberg N, Ahituv N. The role of AUTS2 in neurodevelopment and human evolution. Trends Genet. 2013;29:600–608.
   PubMed Web of Science ®Google Scholar
• Hamshere ML, Green EK, Jones IR, et al. Genetic utility of broadly defined bipolar schizoaffective disorder as a diagnostic concept. Br J Psychiatry. 2009;195:23–29.
   PubMed Web of Science ®Google Scholar
• Hattori E, Toyota T, Ishitsuka Y, et al. Preliminary genome-wide association study of bipolar disorder in the Japanese population. Am J Med Genet B Neuropsychiatr Genet. 2009;150B:1110–1117.
   PubMed Web of Science ®Google Scholar
• Uher R, Ripke S, Müller-Myhsok B, et al. Association of a brain methylation site with clinical outcomes in depression does not replicate across populations. Am J Psychiatry. 2015;172:395–397.
   PubMed Web of Science ®Google Scholar
• Hunter AM, Leuchter AF, Power RA, et al. A genome-wide association study of a sustained pattern of antidepressant response. J Psychiatr Res. 2013;47:1157–1165.
   PubMed Web of Science ®Google Scholar
• Fabbri C, Crisafulli C, Gurwitz D, et al. Neuronal cell adhesion genes and antidepressant response in three independent samples. Pharmacogenomics J. 2015;15:538–548.
   PubMed Web of Science ®Google Scholar
• Moosmang S, Haider N, Klugbauer N, et al. Role of hippocampal Cav1.2 Ca2+ channels in NMDA receptor-independent synaptic plasticity and spatial memory. J Neurosci. 2005;25:9883–9892.
   PubMed Web of Science ®Google Scholar
• Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology. 2008;33:88–109.
   PubMed Web of Science ®Google Scholar
• Tanti A, Belzung C. Neurogenesis along the septo-temporal axis of the hippocampus: are depression and the action of antidepressants region-specific? Neuroscience. 2013;252:234–252.
   PubMed Web of Science ®Google Scholar
• Bronicki LM, Jasmin BJ. Emerging complexity of the HuD/ELAVl4 gene; implications for neuronal development, function, and dysfunction. Rna. 2013;19:1019–1037.
   PubMed Web of Science ®Google Scholar
• Pechnick RN, Zonis S, Wawrowsky K, et al. Antidepressants stimulate hippocampal neurogenesis by inhibiting p21 expression in the subgranular zone of the hipppocampus. PLoS One. 2011;6:e27290.
   PubMed Web of Science ®Google Scholar
• Epp JR, Beasley CL, Galea LA. Increased hippocampal neurogenesis and p21 expression in depression: dependent on antidepressants, sex, age, and antipsychotic exposure. Neuropsychopharmacology. 2013;38:2297–2306.
   PubMed Web of Science ®Google Scholar
• Pedram A, Razandi M, Deschenes RJ, et al. DHHC-7 and −21 are palmitoylacyltransferases for sex steroid receptors. Mol Biol Cell. 2012;23:188–199.
   PubMed Web of Science ®Google Scholar
• Ooishi Y, Kawato S, Hojo Y, et al. Modulation of synaptic plasticity in the hippocampus by hippocampus-derived estrogen and androgen. J Steroid Biochem Mol Biol. 2012;131:37–51.
   PubMed Web of Science ®Google Scholar
• Parker G, Brotchie H. Gender differences in depression. Int Rev Psychiatry. 2010;22:429–436.
   PubMed Web of Science ®Google Scholar
• Sairanen M, O’Leary OF, Knuuttila JE, et al. Chronic antidepressant treatment selectively increases expression of plasticity-related proteins in the hippocampus and medial prefrontal cortex of the rat. Neuroscience. 2007;144:368–374.
   PubMed Web of Science ®Google Scholar
• Park S-H, Choi S-H, Lee J, et al. Effects of repeated citalopram treatments on chronic mild stress-induced growth associated protein-43 mRNA expression in rat hippocampus. Korean J Physiol Pharmacol. 2008;12:117–123.
   PubMed Web of Science ®Google Scholar
• Strawbridge R, Arnone D, Danese A, et al. Inflammation and clinical response to treatment in depression: a meta-analysis. Eur Neuropsychopharmacol. 2015;25:1532–1543.
   PubMed Web of Science ®Google Scholar
• Eyre H, Baune BT. Neuroplastic changes in depression: a role for the immune system. Psychoneuroendocrinology. 2012;37:1397–1416.
   PubMed Web of Science ®Google Scholar
• Hagenaars SP, Harris SE, Davies G, et al. Shared genetic aetiology between cognitive functions and physical and mental health in UK Biobank (N=112 151) and 24 GWAS consortia. Mol Psychiatry. 2016. [Epub ahead of print].
   Web of Science ®Google Scholar
• Tansey KE, Guipponi M, Hu X, et al. Contribution of common genetic variants to antidepressant response. Biol Psychiatry. 2013;73:679–682.
   PubMed Web of Science ®Google Scholar
• Tylee DS, Kawaguchi DM, Glatt SJ. On the outside, looking in: a review and evaluation of the comparability of blood and brain “-omes”. Am J Med Genet B Neuropsychiatr Genet. 2013;162B:595–603.
   PubMed Web of Science ®Google Scholar
• Cattaneo A, Bocchio-Chiavetto L, Zanardini R, et al. Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment. Int J Neuropsychopharmacol. 2010;13:103–108.
   PubMed Web of Science ®Google Scholar
• Lopez JP, Mamdani F, Labonte B, et al. Epigenetic regulation of BDNF expression according to antidepressant response. Mol Psychiatry. 2013;18:398–399.
   PubMed Web of Science ®Google Scholar
• Rojas PS, Fritsch R, Rojas RA, et al. Serum brain-derived neurotrophic factor and glucocorticoid receptor levels in lymphocytes as markers of antidepressant response in major depressive patients: a pilot study. Psychiatry Res. 2011;189:239–245.
   PubMed Web of Science ®Google Scholar
• Mamdani F, Berlim MT, Beaulieu M-M, et al. Gene expression biomarkers of response to citalopram treatment in major depressive disorder. Transl Psychiatry. 2011;1:e13.
   PubMed Web of Science ®Google Scholar
• Hennings JM, Uhr M, Klengel T, et al. RNA expression profiling in depressed patients suggests retinoid-related orphan receptor alpha as a biomarker for antidepressant response. Transl Psychiatry. 2015;5:e538.
   PubMed Web of Science ®Google Scholar
• Belzeaux R, Bergon A, Jeanjean V, et al. Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl Psychiatry. 2012;2:e185.
   PubMed Web of Science ®Google Scholar
• Guilloux J-P, Bassi S, Ding Y, et al. Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression. Neuropsychopharmacology. 2015;40:701–710.
   PubMed Web of Science ®Google Scholar
• Winner J, Allen JD, Altar CA, et al. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl Psychiatry. 2013;3:e242.
   PubMed Web of Science ®Google Scholar
• Hall-Flavin DK, Winner JG, Allen JD, et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genom. 2013;23:535–548.
   PubMed Web of Science ®Google Scholar
• Winner JG, Carhart JM, Altar CA, et al. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. Curr Med Res Opin. 2015;31:1633–1643.
   PubMed Web of Science ®Google Scholar
• Jamerson BD, Payne ME, Garrett ME, et al. Folate metabolism genes, dietary folate and response to antidepressant medications in late-life depression. Int J Geriatr Psychiatry. 2013;28:925–932.
   PubMed Web of Science ®Google Scholar
• Serova LI, Laukova M, Alaluf LG, et al. Intranasal infusion of melanocortin receptor four (MC4R) antagonist to rats ameliorates development of depression and anxiety related symptoms induced by single prolonged stress. Behav Brain Res. 2013;250:139–147.
   PubMed Web of Science ®Google Scholar
• Garriock HA, Tanowitz M, Kraft JB, et al. Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. Am J Psychiatry. 2010;167:565–573.
   PubMed Web of Science ®Google Scholar
• Brennan FX, Gardner KR, Lombard J, et al. A naturalistic study of the effectiveness of pharmacogenetic testing to guide treatment in psychiatric patients with mood and anxiety disorders. Prim Care Companion CNS Disord. 2015;17: e1–e7.
   Google Scholar
• Fagerness J, Fonseca E, Hess GP, et al. Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. Am J Manag Care. 2014;20:e146–e156.
   PubMed Web of Science ®Google Scholar
• Singh AB. Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report. Clin Psychopharmacol Neurosci. 2015;13:150–156.
   PubMed Web of Science ®Google Scholar
• Breitenstein B, Scheuer S, Pfister H, et al. The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study. CNS Spectr. 2014;19:165–175.
   PubMed Web of Science ®Google Scholar
• Breitenstein B, Scheuer S, Brückl TM, et al. Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: results from a randomized clinical study. J Psychiatr Res. 2016;73:86–95.
   PubMed Web of Science ®Google Scholar
• Stamm TJ, Rampp C, Wiethoff K, et al. The FKBP5 polymorphism rs1360780 influences the effect of an algorithm-based antidepressant treatment and is associated with remission in patients with major depression. J Psychopharmacol. 2016;30:40–47.
   PubMed Web of Science ®Google Scholar
• Lee MT, Mahasirimongkol S, Zhang Y, et al. Clinical application of pharmacogenomics: the example of HLA-based drug-induced toxicity. Public Health Genom. 2014;17:248–255.
   PubMed Web of Science ®Google Scholar
• Laje G. Pharmacogenetics of mood disorders: what clinicians need to know. CNS Spectr. 2013;18:272–284.
   PubMed Web of Science ®Google Scholar
• Olgiati P, Bajo E, Bigelli M, et al. Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36:147–154.
   PubMed Web of Science ®Google Scholar
• Katsanis SH, Minear MA, Vorderstrasse A, et al. Perspectives on genetic and genomic technologies in an academic medical center: the duke experience. J Pers Med. 2015;5:67–82.
   PubMed Web of Science ®Google Scholar